Articles from Precisio Biotix Therapeutics, Inc.

Precisio announced the continuation of its expanded access program, with dosing of a staph lysin called ClyO (LYSG101) to a patient with chronic prosthetic joint infection. Under an FDA-approved expanded-access IND, administration of ClyO was initiated on June 1. The treatment follows a 4 month protocol with a minimum 6 month follow-up. Outcomes to be tracked include safety, improvements of clinical signs and symptoms, and either durable eradication or sustained suppression of infection. For this patient, these outcomes were not achievable over the last 7 years, through multiple standard-of-care surgical procedures and long-term antibiotic suppression therapies. After 1 plus months of treatment with ClyO, the dosing has been safe and well-tolerated with no adverse events. While it is too early to fully assess efficacy, the patient’s previously infected knee joint remains culture-negative (i.e., no bacteria detected).